- In patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), dasatinib 140 mg had the lowest level of safety in grade 3-4 hematological adverse events (AEs) while nilotinib 600 and 800 mg had the highest safety levels.
Why this matters
- No prior studies have been published to compare incidence of such AEs with different TKIs.
- Systematic review to investigate the hematological safety profile of TKIs in the treatment of patients with CML.
- A database search yielded 17 studies for inclusion.
- Funding: None.
- Dasatinib 140 mg had the highest probability of being least safe per surface under the cumulative ranking curve analysis (SUCRA) for:
- Anemia: 90%.
- Leukopenia: 87%.
- Neutropenia: 91%.
- Thrombocytopenia: 97%.
- Top 3 TKIs with the lowest probability of being least safe were:
- Anemia: imatinib 600 mg (5%), nilotinib 600 mg (22%), nilotinib 800 mg (36%).
- Leukopenia: nilotinib 800 mg (15%), nilotinib 600 mg (24%), imatinib 600 mg (24%).
- Neutropenia: nilotinib 800 mg (18%), ponatinib (21%), bosutinib (21%).
- Thrombocytopenia: imatinib 600 mg (20%), radotinib 600 mg (28%), nilotinib 800 mg (33%).
- Retrospective data.